To compare the therapeutic efficacy and clinical remission rates of mepolizumab versus benralizumab in patients with severe eosinophilic asthma, highlighting the clinical significance of this comparison.
Key Findings:
Both mepolizumab and benralizumab significantly reduced acute exacerbations and improved asthma control, with benralizumab showing a greater reduction in eosinophil counts and specific pulmonary function metrics.
Interpretation:
The study suggests that while both biologics are effective, benralizumab may offer superior benefits in terms of eosinophil depletion and pulmonary function improvement, which could influence treatment decisions.
Limitations:
Retrospective design may introduce selection bias and limit the ability to establish causality.
Limited generalizability due to the study being conducted at specific centers in Taiwan, which may not reflect broader populations.
Lack of randomization and potential confounding factors not accounted for, which could affect the validity of the findings.
Conclusion:
Benralizumab may provide enhanced clinical outcomes compared to mepolizumab in patients with severe eosinophilic asthma, warranting further prospective studies to confirm these findings and their implications for clinical practice.
Systematic review of 8 observational studies found limited evidence on associations between prenatal asthma-medication exposure and neurodevelopmental outcomes, with autism spectrum disorder the only outcome suitable for meta-analysis.
